Oxaloacetate Research Guide: Krebs Cycle Intermediate for Longevity & Metabolism
Research overview of oxaloacetate (OAA) as a longevity and metabolic compound — its role as a Krebs cycle intermediate, NAD+ precursor effects, caloric restriction mimetic properties, AMPK activation, neuroprotection, and research on anhydrous oxaloacetate (benaGene) at 100-300mg/day.
TL;DR
- Oxaloacetate (OAA) is a Krebs cycle intermediate that acts as a caloric restriction mimetic through AMPK activation and NAD+/NADH ratio shifting
- Research doses: 100-300mg/day of stabilized anhydrous OAA (benaGene)
- Mechanisms: AMPK activation, SIRT1/SIRT3 upregulation, NAD+ elevation, mitochondrial uncoupling
- Neuroprotective effects in animal models; early human research in Alzheimer's disease
- May combine with NMN/NR for complementary NAD+ support through different pathways
Disclaimer: For educational and research purposes only — not medical advice.
Oxaloacetate occupies a unique position in metabolic biochemistry — as a four-carbon intermediate in the Krebs cycle, it participates in carbohydrate, fat, and amino acid metabolism simultaneously. Its role as a supplement is based on the observation that supplemental OAA can shift intracellular metabolism toward a state resembling caloric restriction, activating the same longevity pathways (AMPK, sirtuins) that are activated by fasting and dietary restriction.
Biochemical Mechanisms
AMPK Activation: OAA inhibits succinate dehydrogenase, a Krebs cycle enzyme, causing succinate accumulation and changes in AMP/ATP ratio that activate AMPK. AMPK is the master metabolic sensor that activates catabolic pathways and inhibits mTOR — a key longevity signaling node.
NAD+/NADH Ratio Shift: OAA participates in the malate-aspartate shuttle, consuming NADH in the cytoplasm and producing NAD+. This shifts the NAD+/NADH ratio toward oxidized NAD+ — the same shift produced by fasting and caloric restriction, and required for sirtuin (SIRT1-7) activity.
Sirtuin Activation: Higher NAD+ enables SIRT1 and SIRT3 activation. SIRT1 promotes mitochondrial biogenesis (via PGC-1α), reduces inflammatory gene expression (via NF-κB deacetylation), and activates FOXO longevity transcription factors. SIRT3 protects mitochondria from oxidative damage.
Glutamate/Aspartate Neurotransmitter Balance: OAA is in equilibrium with aspartate and glutamate via transamination. In neurons, this may support neuroprotection by influencing excitatory neurotransmitter metabolism.
Caloric Restriction Mimetic Research
Caloric restriction (CR) extends lifespan in essentially all model organisms studied. Multiple pathways mediate CR's effects: AMPK activation, mTOR inhibition, sirtuin activation, and IGF-1 reduction. CR mimetics are compounds that activate these pathways without food restriction.
OAA alongside Resveratrol, Rapamycin, Metformin, and NMN is studied as a CR mimetic. Comparison:
| CR Mimetic | Primary Target | Key Evidence |
|---|---|---|
| Oxaloacetate | AMPK, NAD+/NADH | Animal lifespan extension; early human trials |
| Metformin | AMPK, Complex I | Diabetic longevity data; TAME trial |
| Rapamycin | mTOR inhibition | Robust lifespan extension across organisms |
| Resveratrol | SIRT1 (indirect) | Animal data; human metabolic benefits |
| NMN/NR | NAD+ precursors | Human safety data; biomarker improvements |
Neuroprotection and Alzheimer's Research
OAA has attracted specific interest in neurodegeneration research:
Alzheimer's disease: A 2019 pilot study (Swerdlow et al.) administered anhydrous OAA 100mg twice daily to Alzheimer's patients for 4 months. Findings included increased frontal and parietal lobe cerebral blood flow (measured by fMRI arterial spin labeling) and some cognitive assessment improvements. This was a small, open-label study but provided a foundation for ongoing investigation.
Mechanism in neurodegeneration: Many neurodegenerative conditions involve mitochondrial dysfunction. OAA's ability to bypass dysfunctional complex I (by entering the ETC through succinate/fumarate pathways) and maintain ATP production in metabolically compromised neurons may explain its neuroprotective effects.
Research Protocols
| Application | Dose | Timing | Notes |
|---|---|---|---|
| General longevity | 100-200mg/day | Morning with food | benaGene (stabilized form) |
| Neuroprotection research | 100mg 2x/day | Morning + midday | Based on Alzheimer's pilot |
| Metabolic optimization | 150-300mg/day | With meals | Some researchers use higher doses |
| Combined with NMN | 100-200mg OAA + 250-500mg NMN | Morning | Complementary NAD+ pathways |
Stability note: Standard OAA degrades rapidly in water. Only stabilized forms (anhydrous oxaloacetate, benaGene) should be used for research — capsule form preferred over dissolved solutions.
Combination Research
OAA's mechanisms complement other longevity compounds:
OAA + NMN/NR: Different NAD+ elevation pathways — OAA shifts NAD+/NADH ratio; NMN/NR provide substrate through salvage pathway. Potentially additive NAD+ effects.
OAA + Resveratrol: OAA elevates NAD+ (substrate for SIRT1); Resveratrol activates SIRT1 directly. Theoretical synergy in sirtuin pathway activation.
OAA + Berberine: Both activate AMPK through different mechanisms (OAA via succinate accumulation; Berberine via Complex I inhibition). May produce additive AMPK/mTOR effects.
Frequently Asked Questions
Q: Is there human data on oxaloacetate's lifespan effects? A: Human lifespan data on OAA doesn't exist (no 80-year human studies). The evidence base consists of: animal model lifespan extension data, biomarker studies (NAD+ elevation, gene expression changes), and the Alzheimer's pilot clinical trial. The CR mimetic theoretical framework provides mechanistic rationale. Human longevity studies (like the TAME Metformin trial) will provide better templates for CR mimetic research design.
Q: Can oxaloacetate cause any adverse effects? A: At research doses (100-300mg/day), stabilized OAA is well-tolerated in the limited human data available. Some subjects report mild GI effects (nausea) when taken on an empty stomach — taking with food resolves this in most cases. OAA's effects on oxalate metabolism are theoretically worth monitoring in subjects with kidney stone history (oxalate being a metabolic neighbor), though this has not been reported as a clinical issue at supplement doses.
Use the Stack Builder Calculator → /calculators/stack
For educational and research purposes only. Not medical advice.
Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.
Written by the Peptide Performance Calculator Research Team
Our team compiles research guides based on published literature for educational purposes. All content is for research use only — not medical advice. Read our disclaimer.
Frequently Asked Questions
What is oxaloacetate and why is it relevant to longevity research?
Oxaloacetate (OAA) is a four-carbon dicarboxylic acid that is a central intermediate in the Krebs (citric acid) cycle, connecting fat and carbohydrate oxidation pathways. As a supplement, stabilized anhydrous oxaloacetate (benaGene) has been researched as a caloric restriction mimetic — it activates AMPK (the cellular energy sensor), shifts the NAD+/NADH ratio toward NAD+ (mimicking a fasted/caloric restricted state), and activates genes in the caloric restriction pathway including SIRT1. This combination of mechanisms drives interest in OAA as a longevity compound.
How does oxaloacetate raise NAD+ levels?
OAA acts as a substrate for the malate-aspartate shuttle, which transfers electrons between cytoplasm and mitochondria. By shifting the NAD+/NADH ratio in favor of NAD+, OAA essentially mimics the metabolic state of fasting or caloric restriction at the cellular level. This is distinct from NMN or NR (which provide NAD+ precursors through the salvage pathway) — OAA raises NAD+ through a different mechanism and the two approaches may be complementary. OAA also directly activates AMPK, which upregulates NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway).
What is benaGene and how does it differ from regular oxaloacetate?
Anhydrous oxaloacetate — sold commercially as benaGene — is a stabilized, crystalline form of OAA that is shelf-stable at room temperature. Regular oxaloacetate is highly unstable and rapidly degrades (half-life of minutes in water at room temperature). benaGene was developed to provide a commercially viable, bioavailable form of OAA that retains biological activity. Research on human subjects has used benaGene specifically; claims about regular oxaloacetate at physiological doses cannot necessarily be extrapolated to standard, unstabilized forms.
New compound guides and calculator updates — no spam, unsubscribe any time.
Free Peptide Calculators
7 free calculators covering reconstitution, dosage, syringe units, half-life, injection volume, stack planning, and cycle duration — no account needed.